ITGAX and Hypoglycemia: In comparison, treatment of CD11c-Cre+Ifnarf/f mice with neutralizing MAbs against C5 reduced liver injury and prevented hypoglycemia compared to animals administered isotype control MAbs (Fig. 8G).